<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.loc.gov/METS/ https://www.loc.gov/standards/mets/mets.xsd" OBJID="oai:wwu.de:b1cfc49a-5e27-49eb-a2fc-684d98548800" LABEL="University of Muenster, Institutional Repository MIAMI"  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
          <mets:metsHdr CREATEDATE="2022-04-07T09:40:59">
            <mets:agent TYPE="OTHER" ROLE="OTHER" OTHERTYPE="SOFTWARE">
              <mets:name>Memory Alpha</mets:name>
            </mets:agent>
          </mets:metsHdr>
          <mets:dmdSec ID="DMD_b1cfc49a-5e27-49eb-a2fc-684d98548800">
            <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
              <mets:xmlData>
                <mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd" version="3.7">
                  <mods:titleInfo type="uniform" lang="eng">
                    <mods:title script="Latn">Influence of a dietary supplement with conjugated linoleic acid (CLA) on systemic immune responses in patients with multiple sclerosis</mods:title>
                  </mods:titleInfo>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/1216192308" altRepGroup="0">
                    <mods:namePart type="given">Flavio Jan</mods:namePart>
                    <mods:namePart type="family">Teipel</mods:namePart>
                    <mods:namePart type="date">1995-</mods:namePart>
                    <mods:displayForm>Teipel, Flavio Jan</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">aut</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/1216192308" altRepGroup="0">
                    <mods:namePart type="given">Flavio</mods:namePart>
                    <mods:namePart type="family">Teipel</mods:namePart>
                    <mods:namePart type="date">1995-</mods:namePart>
                    <mods:displayForm>Teipel, Flavio</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">aut</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/123099781">
                    <mods:namePart type="given">Luisa Hildegard</mods:namePart>
                    <mods:namePart type="family">Klotz</mods:namePart>
                    <mods:namePart type="date">1975-</mods:namePart>
                    <mods:displayForm>Klotz, Luisa Hildegard</mods:displayForm>
                    <mods:affiliation>FB 05: Medizinische Fakultät</mods:affiliation>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">ths</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>ULB Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Landesbibliothek Münster / Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universität Münster / Universitäts- und Landesbibliothek</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:genre>doctoralThesis</mods:genre>
                  <mods:genre authority="dct">Text</mods:genre>
                  <mods:originInfo>
                    <mods:dateIssued keyDate="yes">2020</mods:dateIssued>
                    <mods:dateOther>2020-06-29</mods:dateOther>
                    <mods:issuance>monographic</mods:issuance>
                  </mods:originInfo>
                  <mods:originInfo>
                    <mods:dateIssued encoding="w3cdtf">2020-08-19</mods:dateIssued>
                    <mods:dateModified encoding="w3cdtf">2020-09-07</mods:dateModified>
                    <mods:edition>[Electronic ed.]</mods:edition>
                  </mods:originInfo>
                  <mods:language>
                    <mods:languageTerm type="code" authority="iso639-2b">eng</mods:languageTerm>
                  </mods:language>
                  <mods:physicalDescription>
                    <mods:form>electronic</mods:form>
                    <mods:reformattingQuality>access</mods:reformattingQuality>
                    <mods:internetMediaType>application/pdf</mods:internetMediaType>
                    <mods:digitalOrigin>born digital</mods:digitalOrigin>
                  </mods:physicalDescription>
                  <mods:abstract lang="ger">Eine Nahrungsergänzung mit CLA erscheint als vielversprechender Ansatz für die komplementäre MS Therapie. Hier wurde der Einfluss von CLA auf systemische humane Immunantworten genauer untersucht. Untersuchungen der Zytokinproduktion und des Zellmetabolismus von in vitro mit CLA behandelten CD4+ T Zellen gesunder Proband*innen deuteten auf anti-inflammatorische Eigenschaften von CLA hin. In einer explorativen klinischen Studie wurden 15 Patient*innen mit schubförmiger MS für 24 Wochen mit 2,1 g CLA per os täglich behandelt. Durchflusszytometrische und metabolische Untersuchungen ihrer peripheren Immunzellen deuteten überwiegend ebenfalls auf anti-inflammatorische Effekte von CLA hin, vermittelt insbesondere über das adaptive Immunsystem. Klinisch zeigten sich keine deutlichen Veränderungen und die Nahrungsergänzung mit CLA wurde überwiegend gut vertragen. Zukünftige, größere und placebokontrollierte Studien sollten den Wirkmechanismus, die Wirksamkeit und die Verträglichkeit von CLA bei MS weiter untersuchen.</mods:abstract>
                  <mods:abstract lang="eng">A dietary supplementation with CLA appears as a promising approach for the complementary MS treatment. Here, the influence of CLA on systemic human immune responses was further investigated. Analyses of the cytokine production and the cell metabolism of healthy controls’ CD4+ T cells treated in vitro with CLA suggested anti-inflammatory effects of CLA. In an exploratory clinical trial, 15 patients with relapsing-remitting MS were treated with 2.1 g CLA per os daily for 24 weeks. Flow cytometric and metabolic investigations of their peripheral immune cells predominantly suggested anti-inflammatory effects of CLA as well, particularly mediated via the adaptive immune system. Clinically, no major changes occurred and the dietary supplementation with CLA was overall well tolerated. Future, larger and placebo-controlled trials should further investigate the mechanism of action, efficacy and tolerability of CLA in MS.</mods:abstract>
                  <mods:tableOfContents lang="eng">Abbreviations ..... 10&#13;
1 Introduction ..... 14&#13;
1.1 Multiple sclerosis ..... 14&#13;
1.1.1 Epidemiology ..... 14&#13;
1.1.2 Clinic ..... 14&#13;
1.1.2.1 Symptoms ..... 15&#13;
1.1.2.2 Clinical course ..... 15&#13;
1.1.2.3 Diagnosis ..... 16&#13;
1.1.3 Current therapy options ..... 17&#13;
1.1.4 Pathogenesis ..... 17&#13;
1.1.4.1 Lesional and systemic immune system alterations..... 18&#13;
1.1.4.2 Genetic influences ..... 21&#13;
1.1.4.3 Environmental influences ..... 22&#13;
1.1.4.4 Immune cell metabolism in MS ..... 26&#13;
1.2 Conjugated linoleic acid ..... 30&#13;
1.2.1 Chemical aspects ..... 30&#13;
1.2.2 Occurrence in food items and natural intake ..... 31&#13;
1.2.3 Effects in the context of inflammatory diseases ..... 31&#13;
1.2.3.1 Effects on the immune system ..... 32&#13;
1.2.3.2 Effects on inflammatory diseases ..... 32&#13;
1.2.3.3 Effects in the context of CNS autoimmunity ..... 33&#13;
1.2.4 Discussed modes of action ..... 35&#13;
1.2.4.1 CLA influencing the immune system directly ..... 36&#13;
1.2.4.2 CLA influencing the immune cell metabolism ..... 36&#13;
1.2.4.3 CLA influencing the gut microbiota ..... 37&#13;
1.2.4.4 CLA metabolites as key molecules ..... 38&#13;
1.3 Aim of the thesis ..... 39&#13;
2 Material ..... 40&#13;
2.1 Devices ..... 40&#13;
2.2 Disposables ..... 40&#13;
2.3 Study medication ..... 41&#13;
2.4 Constituents of media and buffers ..... 41&#13;
2.5 Composition of media and buffers ..... 42&#13;
2.6 Chemicals and reagents ..... 43&#13;
2.7 Assay kits ..... 43&#13;
2.8 Antibodies for cell activation ..... 44&#13;
2.9 Antibodies for flow cytometry ..... 44&#13;
2.10 Software ..... 47&#13;
3 Methods ..... 48&#13;
3.1 Biological sample acquisition ..... 48&#13;
3.1.1 Clinical study ..... 48&#13;
3.1.1.1 Inclusion and exclusion criteria ..... 48&#13;
3.1.1.2 Study design ..... 49&#13;
3.1.1.3 Analysis of baseline demographical and clinical data ..... 50&#13;
3.1.1.4 Analysis of natural fat and CLA intake 51&#13;
3.1.2 HC samples ..... 51&#13;
3.2 Cell culture ..... 52&#13;
3.2.1 PBMC isolation ..... 52&#13;
3.2.2 PBMC thawing ..... 52&#13;
3.2.3 Determination of cell concentrations ..... 53&#13;
3.2.3.1 Manual cell counting ..... 53&#13;
3.2.3.2 Automatic cell counting ..... 53&#13;
3.2.4 Adjustment of cell concentrations ..... 53&#13;
3.2.5 CD4+ T cell isolation ..... 54&#13;
3.2.6 Cell activation ..... 54&#13;
3.2.6.1 PHA activation ..... 54&#13;
3.2.6.2 LAC activation ..... 55&#13;
3.2.6.3 PMA / ionomycin activation ..... 55&#13;
3.2.6.4 anti-CD3 and anti-CD28 activation 55&#13;
3.2.7 in vitro CLA Treatment ..... 55&#13;
3.3 Analytical methods ..... 55&#13;
3.3.1 Enzyme-linked immunosorbent assay (ELISA) ..... 55&#13;
3.3.2 Luminex® assay ..... 57&#13;
3.3.3 Propidium iodide (PI) staining ..... 58&#13;
3.3.4 Flow cytometry ..... 58&#13;
3.3.4.1 Surface staining at 4 °C ..... 59&#13;
3.3.4.2 Surface staining at 37 °C ..... 60&#13;
3.3.4.3 Combined surface and intracellular staining at 4 °C ..... 61&#13;
3.3.4.4 Combined surface and intracellular staining at 37 °C / 4 °C ..... 62&#13;
3.3.4.5 Combined surface and intracellular staining at 4 °C after LAC stimulation ..... 62&#13;
3.3.4.6 Data analysis ..... 63&#13;
3.3.5 Metabolism analysis ..... 67&#13;
3.4 Statistical methods ..... 73&#13;
3.4.1 Descriptive statistics ..... 73&#13;
3.4.2 Inferential statistics ..... 74&#13;
3.4.3 Handling of values &lt; LLOQ or &gt; ULOQ ..... 74&#13;
3.4.3.1 Values &lt; LLOQ ..... 75&#13;
3.4.3.2 Values &gt; ULOQ ..... 75&#13;
4 Results ..... 76&#13;
4.1 in vitro experiments ..... 76&#13;
4.1.1 Cytotoxicity investigation ..... 76&#13;
4.1.2 CD4+ T cell cytokine production upon activation ..... 77&#13;
4.1.2.1 Quantification in an ELISA assay ..... 77&#13;
4.1.2.2 Quantification in a Luminex® assay ..... 78&#13;
4.1.3 CD4+ T cell metabolism ..... 80&#13;
4.2 Clinical study ..... 82&#13;
4.2.1 Baseline demographical and clinical data ..... 82&#13;
4.2.2 Natural fat and CLA intake ..... 83&#13;
4.2.2.1 Fat intake ..... 83&#13;
4.2.2.2 CLA intake ..... 84&#13;
4.2.3 Clinical study endpoints ..... 85&#13;
4.2.3.1 Adherence to study medication ..... 85&#13;
4.2.3.2 Relapses ..... 85&#13;
4.2.3.3 EDSS during follow-up ..... 85&#13;
4.2.3.4 Paraclinical data ..... 86&#13;
4.2.3.5 Correlation of relapses, EDSS during follow-up and paraclinical data .... 86&#13;
4.2.3.6 Adverse events ..... 87&#13;
4.2.4 In-depth functional immune phenotyping ..... 88&#13;
4.2.4.1 CD4+ T cells ..... 89&#13;
4.2.4.2 CD8+ T cells ..... 92&#13;
4.2.4.3 B cells ..... 94&#13;
4.2.4.4 CD4+ Treg cells ..... 96&#13;
4.2.5 CD4+ T cell cytokine production upon activation 97&#13;
4.2.6 CD4+ T cell metabolism ..... 98&#13;
4.2.6.1 Oxidative phosphorylation (OXPHOS) ..... 99&#13;
4.2.6.2 Glycolysis ..... 101&#13;
5 Discussion ..... 105&#13;
5.1 Clinical data ..... 105&#13;
5.1.1 Baseline demographical and clinical data 105&#13;
5.1.2 Natural fat and CLA intake ..... 106&#13;
5.1.3 Adherence to study medication ..... 107&#13;
5.1.4 Relapses, EDSS and paraclinical development during follow-up ..... 108&#13;
5.1.5 Adverse events ..... 110&#13;
5.2 In-depth functional immune phenotyping ..... 110&#13;
5.2.1 CD4+ T cells ..... 111&#13;
5.2.1.1 TH17 cells and related immune cell subsets ..... 111&#13;
5.2.1.2 CD4+ T cell cytokine production ..... 113&#13;
5.2.2 CD8+ T cells ..... 114&#13;
5.2.2.1 CD226 expression on CD8+ T cells ..... 114&#13;
5.2.2.2 CD8+ T cell cytokine production ..... 116&#13;
5.2.3 B cells ..... 117&#13;
5.2.4 CD4+ Treg cells ..... 118&#13;
5.2.5 Methodological limitations ..... 122&#13;
5.3 CD4+ T cell cytokine production upon activation ..... 122&#13;
5.4 CD4+ T cell metabolism ..... 127&#13;
5.5 Study limitations ..... 131&#13;
5.6 Gut microbiota ..... 134&#13;
5.7 Outlook ..... 135&#13;
6 Summary ..... 137&#13;
Figures ..... 138&#13;
Tables ..... 140&#13;
Literature ..... 141&#13;
Acknowledgments ..... 163&#13;
Curriculum vitae ..... 164&#13;
Appendix ..... I</mods:tableOfContents>
                  <mods:targetAudience>specialized</mods:targetAudience>
                  <mods:note type="thesis">Münster (Westfalen), Univ., Diss., 2020</mods:note>
                  <mods:subject>
                    <mods:topic lang="ger">konjugierte Linolsäure (CLA); Multiple Sklerose (MS); Nahrungsergänzung; CD4+ T Zellen; Immunsystem; Entzündung; Autoimmunerkrankung</mods:topic>
                  </mods:subject>
                  <mods:subject>
                    <mods:topic lang="eng">conjugated linoleic acid (CLA); multiple sclerosis (MS); dietary supplement; CD4+ T cells; immune system; inflammation; autoimmune disease</mods:topic>
                  </mods:subject>
                  <mods:classification authority="ddc">610</mods:classification>
                  <mods:identifier type="urn">urn:nbn:de:hbz:6-60139604050</mods:identifier>
                  <mods:location>
                    <mods:url access="object in context">https://miami.uni-muenster.de/Record/b1cfc49a-5e27-49eb-a2fc-684d98548800</mods:url>
                  </mods:location>
                  <mods:accessCondition type="use and reproduction">
                    <mods:extension>
                      <ma:maWrap xmlns:ma="http://memoryalpha.ulb.uni-muenster.de">
                        <ma:licence>
                          <ma:displayLabel>InC 1.0</ma:displayLabel>
                          <ma:targetUrl>https://rightsstatements.org/vocab/InC/1.0/</ma:targetUrl>
                        </ma:licence>
                      </ma:maWrap>
                    </mods:extension>
                  </mods:accessCondition>
                  <mods:recordInfo>
                    <mods:recordIdentifier>oai:wwu.de:b1cfc49a-5e27-49eb-a2fc-684d98548800</mods:recordIdentifier>
                  </mods:recordInfo>
                </mods:mods>
              </mets:xmlData>
            </mets:mdWrap>
          </mets:dmdSec>
          <mets:amdSec ID="AMD_b1cfc49a-5e27-49eb-a2fc-684d98548800">
            <mets:rightsMD ID="RIGHTSMD_b1cfc49a-5e27-49eb-a2fc-684d98548800">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVRIGHTS">
                <mets:xmlData>
                  <dv:rights xmlns:dv="http://dfg-viewer.de/">
                    <dv:owner>Universitäts- und Landesbibliothek Münster</dv:owner>
                  </dv:rights>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:rightsMD>
            <mets:digiprovMD ID="DIGIPROVMD_b1cfc49a-5e27-49eb-a2fc-684d98548800">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVLINKS">
                <mets:xmlData>
                  <dv:links xmlns:dv="http://dfg-viewer.de/">
                    <dv:reference>https://miami.uni-muenster.de/Record/b1cfc49a-5e27-49eb-a2fc-684d98548800</dv:reference>
                    <dv:presentation/>
                  </dv:links>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:digiprovMD>
          </mets:amdSec>
          <mets:fileSec>
            <mets:fileGrp USE="DEFAULT">
              <mets:file MIMETYPE="application/pdf" CHECKSUM="919863594b80d0e1060a732196d982c494bca72a26449f01ac188216ddab8d22" CREATED="2020-09-07T15:39:46" CHECKSUMTYPE="SHA-256" SIZE="3837028" ID="ID_FIL_diss_teipel.pdf_DEFAULT">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/b1cfc49a-5e27-49eb-a2fc-684d98548800/diss_teipel.pdf" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
            <mets:fileGrp USE="DOWNLOAD">
              <mets:file MIMETYPE="application/pdf" ID="DOWb1cfc49a-5e27-49eb-a2fc-684d98548800">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/transfer/miami/b1cfc49a-5e27-49eb-a2fc-684d98548800" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
          </mets:fileSec>
          <mets:structMap TYPE="PHYSICAL">
            <mets:div ID="ID_PHY_b1cfc49a-5e27-49eb-a2fc-684d98548800" TYPE="physSequence">
              <mets:div ID="ID_PHY_diss_teipel.pdf">
                <mets:fptr FILEID="ID_FIL_diss_teipel.pdf_DEFAULT"/>
              </mets:div>
            </mets:div>
          </mets:structMap>
          <mets:structMap TYPE="LOGICAL">
            <mets:div ADMID="AMD_b1cfc49a-5e27-49eb-a2fc-684d98548800" DMDID="DMD_b1cfc49a-5e27-49eb-a2fc-684d98548800" ID="ID_LOG_b1cfc49a-5e27-49eb-a2fc-684d98548800" TYPE="Monograph">
              <mets:div ID="ID_LOG_ID_PHY_diss_teipel.pdf"/>
            </mets:div>
          </mets:structMap>
          <mets:structLink>
            <mets:smLink xlink:from="ID_LOG_b1cfc49a-5e27-49eb-a2fc-684d98548800" xlink:to="ID_PHY_b1cfc49a-5e27-49eb-a2fc-684d98548800"/>
            <mets:smLink xlink:from="ID_LOG_ID_PHY_diss_teipel.pdf" xlink:to="ID_PHY_diss_teipel.pdf"/>
          </mets:structLink>
        </mets:mets>